U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07137104) titled 'Safety and Preliminary Effectiveness Study of Mesenchymal Stem Cells, HeXell-2020, in Patients With Stable Coronary Artery Disease' on July 17.
Brief Summary: This is a phase I/IIa study to investigate the safety, tolerability, and preliminary effectiveness of HeXell-2020 in patients with stable coronary artery disease (CAD). HeXell-2020 is an investigational drug product consisting of allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance. All enrolled and eligible subjects will receive HeXell-2020 treatment.
Study Start Date: Dec. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Coronary Artery Disease
I...